Therapeutic potential of human induced pluripotent stem cells and renal progenitor cells in experimental chronic kidney disease.
Patrícia de Carvalho RibeiroFernando Henrique LojudiceIda Maria Maximina Fernandes-CharpiotMaria Alice Sperto Ferreira BaptistaStanley de Almeida AraújoGloria Elisa Florido MendesMari Cleide SogayarMario Abbud-FilhoHeloisa Cristina CaldasPublished in: Stem cell research & therapy (2020)
In conclusion, we describe that both MMC-treated hiPSCs and RPCs exert beneficial effects in attenuating CKD progression. Both cell types were equally efficient to reduce histological damage and weight loss caused by CKD. hiPSCs seem to be more efficient than RPCs, possibly due to a paracrine effect triggered by hiPSCs. These results demonstrate that the use of MMC-treated hiPSCs and RPCs improves clinical and histological CKD parameters, avoided tumor formation, and therefore may be a promising cell therapy strategy for CKD.